Editas Medicine Announces Second Quarter 2025 Results and Business Updates
Provided By GlobeNewswire
Last update: Aug 12, 2025
Company to select lead development candidate in September; on track to file IND by mid-2026 and achieve human proof-of-concept by year-end 2026
First IND/CTA accepted for CD19 HD Allo CAR T program as part of collaboration with Bristol Myers Squibb, triggering milestone payment to Editas
Read more at globenewswire.com
